Trial Profile
A large, multicenter, 3-year extension study assessing efficacy and safety of onabotulinumtoxinA (onabotA) for treatment of urinary incontinence due to neurogenic detrusor overactivity (NDO) in patients not adequately managed with an anticholinergic
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Jan 2018
Price :
$35
*
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Urinary incontinence
- Focus Therapeutic Use
- 26 Dec 2015 New trial record